Related Experiment Video
Updated: May 15, 2026

Chemiluminescence-based Assays for Detection of Nitric Oxide and its Derivatives from Autoxidation and Nitrosated Compounds
Published on: February 16, 2022
Novel s-nitrosothiols have potential therapeutic uses for cystic fibrosis
Khalequz Zaman1, Maya Fraser-Butler, Deric Bennett
1Division of Pediatric Respiratory Medicine, University of Virginia School of Medicine, 409 Lane Road, Charlottesville, VA 22908, USA. kz2n@virginia.edu
Abstract:
Cystic fibrosis (CF) is a multisystem disease associated with mutations in the gene that encodes the CF transmembrane conductance regulatory (CFTR) protein. The majority of wild-type CFTR and virtually all mutant ΔF508 CFTR are degraded before reaching the cell surface. Certain agents and conditions that increase expression and maturation of CFTR enable the protein to function at the cell surface. We and several research groups have reported that S-nitrosoglutathione (GSNO), a class of endogenous S-nitrosothiols, increases the maturation and function of CFTR in human airway epithelial cells. S-nitrosothiols (SNOs) are endogenous molecules with several cell signaling effects and potential relevance to human lung disease. SNOs are normally present in the human airway and have beneficial effects on lung function. Biochemical evidence suggests that SNOs act on post-translational protein modifications through mechanisms involving S-nitrosylation reactions. S-nitrosylation reactions are increasingly recognized to represent metabolically regulated cell signaling processes. Airway epithelial S-nitrosylation signaling disorders have been observed in a range of diseases, including CF. SNO levels are low in CF patients and normal physiological concentrations are effective in increasing CFTR maturation. The mechanisms by which SNOs improve CFTR expression appear to be novel. However, the precise mechanisms by which SNOs exert their beneficial effects are poorly understood. In the near future, we expect to identify the novel mechanisms by which SNO augments CFTR maturation. This information will be critical for optimizing the design and dosing of SNOs that might be used as CFTR corrector therapies in clinical trials.
Insights
S-nitrosothiols (SNOs) enhance the maturation and function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein in airway cells. Restoring SNO levels may offer a novel therapeutic strategy for cystic fibrosis treatment.
Area of Science:
- Cellular Biology
- Molecular Medicine
- Respiratory Diseases
Background:
- Cystic fibrosis (CF) is a genetic disorder caused by mutations in the CF transmembrane conductance regulator (CFTR) gene, leading to protein misfolding and degradation.
- Most CFTR protein, including the common ΔF508 mutation, is degraded before reaching the cell surface, impairing its function.
- S-nitrosothiols (SNOs), endogenous signaling molecules, are known to influence protein function and are present in the human airway.
Purpose of the Study:
- To investigate the role of S-nitrosothiols (SNOs) in enhancing the maturation and function of CFTR protein.
- To explore the potential of SNOs as a therapeutic strategy for cystic fibrosis by improving CFTR protein processing.
- To understand the underlying mechanisms by which SNOs impact CFTR maturation in airway epithelial cells.
Main Methods:
- Utilized human airway epithelial cells to study CFTR protein maturation and function.
- Administered S-nitrosoglutathione (GSNO), an endogenous S-nitrosothiol, to assess its effects on CFTR.
- Investigated post-translational protein modifications, specifically S-nitrosylation, as a potential mechanism of action.
Main Results:
- S-nitrosoglutathione (GSNO) was found to increase the maturation and function of CFTR in human airway epithelial cells.
- SNO levels are reduced in cystic fibrosis patients, and physiological concentrations of SNOs effectively enhance CFTR maturation.
- Evidence suggests SNOs act through S-nitrosylation reactions, a regulated cell signaling process.
Conclusions:
- S-nitrosothiols (SNOs) demonstrate a novel mechanism for augmenting CFTR maturation and function.
- The beneficial effects of SNOs in CFTR processing offer a promising avenue for developing new CF therapies.
- Further research into the precise mechanisms of SNO action is crucial for optimizing SNO-based CFTR corrector therapies for clinical trials.
Related Concept Videos
Cystic Fibrosis: Management
Sinus disease and chronic sinusitis...
Cystic Fibrosis: Pathogenesis
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation, but...
Preparation and Reactions of Thiols
Structure and Nomenclature of Thiols and Sulfides
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...
2° Amines to N-Nitrosamines: Reaction with NaNO2

